A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
Human Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 181 moreA Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Healthy Females Aged 18-30 Years.
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)...
Human Papillomavirus InfectionThis study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and Adacel™.
Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers
Human Papillomavirus InfectionThe primary objectives of this study are to determine the acceptance and potential for the effective use of HPV vaccine in the standard and a modified schedule in female sex workers. Secondary objectives include ascertaining the prevalence of HPV types among female sex workers by age and sexual experience.
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
HPV InfectionsThe study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Cervical CancerVulvar Cancer3 moreThe purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
HumanPapillomavirus InfectionsThis study is to evaluate the safety, tolerability, and immune response of an investigational vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma Virus (HPV).
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old...
Papillomavirus InfectionsUterine Cervical Neoplasms4 moreThis study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam. The study hypothesis states that V503 induces acceptable anti-human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion at 4 weeks postdose 3.
Thermocoagulation for Treatment of Precancerous Cervical Lesions
Human Immunodeficiency VirusHPV Infection1 moreThe purpose of this study is to evaluate the safety, acceptability, and efficacy of Thermocoagulation for treatment of precancerous lesions among HIV-positive women in a screen-and-treat program in Western Kenya.
A Comparison of Cotton and Flocked Swabs for Vaginal Self Collection
Human Papillomavirus InfectionThe purpose of this study is to compare the performance of cotton and flocked swabs for vaginal self-sampling.
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
Cancer SurvivorPrevention of Human Papillomavirus InfectionThis trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadrivalent and nonavalent HPV vaccine in young cancer survivors.